Recent Updates
Recently added Catalysts
ABUS

Arbutus to Participate at Wedbush PacGrow Healthcare Conference

Key Takeaway: WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday,

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
2%
average across 5 past catalysts
Cash runway
~46 mo
Minimal dilution risk
Lead asset
TKM-080301
Phase 1 · Cancer

Full Press Release Details

WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 10:55 am ET in New York.
A live webcast of the fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.  A replay of the webcast will be available for 90 days following the live presentations.
Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Investor Relations Consultant
Last updated: Aug 6, 2019